NLRP3 and metabolic dysfunction-associated steatohepatitis: Further support for the role of NLRP3 in NASH was provided by blocking NRLP3 inflammasome with a specific antagonist, IFM-514, in mice fed a methionine/choline-deficient diet (MCD), resulting in reduced caspase-1 activation, decreased hepatic steatosis, inflammation, and fibrosis [9].